Use of medications in Wolff-Parkinson-White syndrome.
The diagnosis of Wolff-Parkinson-White syndrome is generally straightforward; however, the management may not be, and requires an understanding of the competing risks of various treatment options and that of the clinical setting in which the diagnosis is made. The symptomatic patient with Wolff-Parkinson-White has an increased risk of atrial fibrillation and a small but significant risk of sudden cardiac death. Therapy is based on reduction in symptom burden and attenuation of the risk of pre-excited atrial fibrillation. Catheter ablation is the most effective means of achieving this goal with abolition of symptoms and risk of pre-excited atrial fibrillation. Medication is often employed in the acute setting to terminate paroxysms of arrhythmia associated with the accessory pathway and reduce the subsequent burden of symptoms until ablation can be performed. An overview of the agents commonly used is provided together with recommendations.
Redfearn
D P
DP
Division of Cardiology, University of Western Ontario, London, Ontario, Canada.
Krahn
A D
AD
Skanes
A C
AC
Yee
R
R
Klein
G J
GJ
D000889:Anti-Arrhythmia Agents / Q000145:classification / Q000627:therapeutic use*; D004562:Electrocardiography / Q000187:drug effects; D006801:Humans; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents